Intangible Assets

MYO does not appear to have a durable brand, proprietary IP, or regulatory franchise that lets it command structurally better pricing than peers, which is consistent with deeply negative TTM ROIC and ROCE.

The absence of disclosed multi-year margin or return history in the provided metrics limits evidence of persistent intangible-led pricing power, while peers with stronger clinical or platform differentiation would typically show better capital returns.

Any product or technology differentiation appears insufficient to translate into durable customer willingness to pay, because the company is still generating materially negative returns on invested capital.

Switching Costs

The business does not show evidence of high customer lock-in or workflow dependency, because negative returns and weak capital efficiency suggest customers can substitute alternatives without meaningful friction.

Compared with peers that embed products into clinical, operational, or data workflows, MYO appears to have limited retention leverage and limited ability to raise prices without volume loss.

The provided metrics do not indicate a recurring-revenue or installed-base structure strong enough to create material switching costs over a 5–10 year horizon.

Network Effects

MYO shows no clear evidence of a self-reinforcing user, data, or ecosystem loop that would make the product more valuable as adoption rises.

Unlike peers with platform-like distribution or data accumulation, the company’s negative ROIC suggests any usage base is not yet compounding into durable competitive advantage.

The available metrics do not support peer-dependent network effects, so customer value appears to be driven more by product utility than by ecosystem scale.

Cost Advantage

MYO does not demonstrate a visible cost advantage versus peers, because negative ROIC and ROCE indicate it is not converting operating activity into superior unit economics.

The cash conversion cycle of 93 days suggests working-capital intensity rather than a structurally lean cost structure, which weakens pricing flexibility relative to better-positioned competitors.

Without evidence of scale purchasing, manufacturing leverage, or lower service costs, the company looks more replicable than cost advantaged.

Efficient Scale

MYO does not appear to operate in a clearly protected niche where a small number of suppliers can profitably serve the market without inviting competition, which limits efficient-scale protection.

The negative return profile implies the market is not yet supporting a durable oligopoly-like structure that would preserve margins versus peers.

Compared with companies that benefit from regulated, capacity-constrained, or highly concentrated markets, MYO shows little evidence that market size alone is shielding it from competitive pressure.

Overall Score

MYO’s moat appears weak versus peers because the provided metrics show deeply negative ROIC/ROCE and no evidence of durable pricing power, switching costs, network effects, or efficient-scale protection; any differentiation is not yet translating into sustained retention or margin resilience over a 5–10 year horizon.